-
1
-
-
0027534992
-
The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period
-
Davis C., Rohatiner A., Lim J., Whelan J., Oza A., Amess J., Love S., Stead E., Lister T. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 1993; 83: 404 – 11
-
(1993)
Br J Haematol
, vol.83
, pp. 404-411
-
-
Davis, C.1
Rohatiner, A.2
Lim, J.3
Whelan, J.4
Oza, A.5
Amess, J.6
Love, S.7
Stead, E.8
Lister, T.9
-
2
-
-
0024379549
-
Response to salvage therapy and survival after relapse in acute myelogenous leukemia
-
Keating M., Kantarjian H., Smith T., Estey E., Walters R., Andersson B., Beran M., McCredie K., Freiretch E. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin One 1989; 7 (8) 1071 – 9
-
(1989)
J Clin One
, vol.7
, Issue.8
, pp. 1071-1079
-
-
Keating, M.1
Kantarjian, H.2
Smith, T.3
Estey, E.4
Walters, R.5
Andersson, B.6
Beran, M.7
McCredie, K.8
Freiretch, E.9
-
3
-
-
0025273524
-
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by Thioguanine, cytosine Arabinoside, and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy
-
Hiddemann W., Martin W., Sauerland C., Heinecke A., Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by Thioguanine, cytosine Arabinoside, and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4: 184 – 8
-
(1990)
Leukemia
, vol.4
, pp. 184-188
-
-
Hiddemann, W.1
Martin, W.2
Sauerland, C.3
Heinecke, A.4
Buchner, T.5
-
4
-
-
0023028589
-
Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
-
Rees J., Swirsky D., Gray R., Hayhoe F. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 1236 – 41
-
(1986)
Lancet
, pp. 1236-1241
-
-
Rees, J.1
Swirsky, D.2
Gray, R.3
Hayhoe, F.4
-
5
-
-
0023816181
-
Impact of rein-duction regimens on the clinical course of adult acute nonlymphocytic leukemia
-
Welborn J., Lewis J., Meyers F. Impact of rein-duction regimens on the clinical course of adult acute nonlymphocytic leukemia. Leukemia 1988; 2: 711 – 6
-
(1988)
Leukemia
, vol.2
, pp. 711-716
-
-
Welborn, J.1
Lewis, J.2
Meyers, F.3
-
6
-
-
0020546405
-
High-dose cytosine arabinoside therapy for refractory leukemia
-
Herzig R., Wolff S., Lazarus H., Phillips G., Karanes C., Herzig G. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361 – 9
-
(1983)
Blood
, vol.62
, pp. 361-369
-
-
Herzig, R.1
Wolff, S.2
Lazarus, H.3
Phillips, G.4
Karanes, C.5
Herzig, G.6
-
7
-
-
0028077347
-
A phase III trial of high-dose cytarabine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia a Southeastern Cancer Study Group trial
-
Vogler W. R., McCarley D. L., Stagg M., Bartolucci A. A., Moore J., Martelo O., Omura G. A. A phase III trial of high-dose cytarabine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia a Southeastern Cancer Study Group trial. Leukemia 1994; 8 (11) 1847 – 53
-
(1994)
Leukemia
, vol.8
, Issue.11
, pp. 1847-1853
-
-
Vogler, W.R.1
McCarley, D.L.2
Stagg, M.3
Bartolucci, A.A.4
Moore, J.5
Martelo, O.6
Omura, G.A.7
-
8
-
-
0029943332
-
A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia
-
Estey E., Kornblau S., Pierce S., Kantarjian H., Beran M., Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996; 88 (2) 756
-
(1996)
Blood
, vol.88
, Issue.2
, pp. 756
-
-
Estey, E.1
Kornblau, S.2
Pierce, S.3
Kantarjian, H.4
Beran, M.5
Keating, M.6
-
9
-
-
0023253647
-
Prognostic factors in adult patients with acute leukemia at first relapse
-
Smits P., Schoots L., De Pauw B., De Witte T., Holdrinet R., Janssen J., Haanen C. Prognostic factors in adult patients with acute leukemia at first relapse. Cancer 1987; 1631 – 4
-
(1987)
Cancer
, pp. 1631-1634
-
-
Smits, P.1
Schoots, L.2
De Pauw, B.3
De Witte, T.4
Holdrinet, R.5
Janssen, J.6
Haanen, C.7
-
10
-
-
0017280493
-
VP-16–213 in acute myelogenous leukemia
-
Smith I., Clink H., Gerken M., McElwain T. VP-16–213 in acute myelogenous leukemia. Postgraduate Medical Journal 1976, 52: 66 – 70
-
(1976)
Postgraduate Medical Journal
, Issue.52
, pp. 66-70
-
-
Smith, I.1
Clink, H.2
Gerken, M.3
McElwain, T.4
-
11
-
-
0013244016
-
A phase II trial of VP-16–213 in adults with refractory acute myelogenous leukemia
-
Bennet J., Lymann G., Cassilith P., Glick J., Oken M. A phase II trial of VP-16–213 in adults with refractory acute myelogenous leukemia. Am J Clin Path 1984; 7: 471 – 3
-
(1984)
Am J Clin Path
, vol.7
, pp. 471-473
-
-
Bennet, J.1
Lymann, G.2
Cassilith, P.3
Glick, J.4
Oken, M.5
-
12
-
-
0020453093
-
Etoposide in the treatment of acute leukemia in adults
-
Varini M., Cavilli F. Etoposide in the treatment of acute leukemia in adults. Cancer Treat Rev 1982; 9: 59 – 62
-
(1982)
Cancer Treat Rev
, vol.9
, pp. 59-62
-
-
Varini, M.1
Cavilli, F.2
-
13
-
-
0028122277
-
Carboplatin and etoposide in acute myeloid leukemia
-
Sanz M. A., Bonanad S., Sanz G. F., Martin G. Carboplatin and etoposide in acute myeloid leukemia. Leukemia 1994; 8: 1599 – 600
-
(1994)
Leukemia
, vol.8
, pp. 1599-1600
-
-
Sanz, M.A.1
Bonanad, S.2
Sanz, G.F.3
Martin, G.4
-
14
-
-
6844256087
-
A phase II clinical trial of carboplatin in relapsed and refractory leukemia by the Eastern Cooperative Oncology Group. [Abstract]
-
Vogler W., Lazarus H., Winton E., et al. A phase II clinical trial of carboplatin in relapsed and refractory leukemia by the Eastern Cooperative Oncology Group. [Abstract]. Blood 1990; 76 (Supplement 1) 332
-
(1990)
Blood
, vol.76
, pp. 332
-
-
Vogler, W.1
Lazarus, H.2
Winton, E.3
-
15
-
-
0026057127
-
A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphocytic leukemia
-
Martinez J. A., Martin G., Sanz G. F., Sempere A., Jarque I., de la Rubia J., Sanz M. A. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphocytic leukemia. J Clin One 1991; 9: 39 – 43
-
(1991)
J Clin One
, vol.9
, pp. 39-43
-
-
Martinez, J.A.1
Martin, G.2
Sanz, G.F.3
Sempere, A.4
Jarque, I.5
de la Rubia, J.6
Sanz, M.A.7
-
16
-
-
0023713591
-
Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia
-
Lee E., Egorin M., Van Echo D., Cohen A., Tait N., Schiffler C. A. Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. JNCI 1988; 80: 131 – 5
-
(1988)
JNCI
, vol.80
, pp. 131-135
-
-
Lee, E.1
Egorin, M.2
Van Echo, D.3
Cohen, A.4
Tait, N.5
Schiffler, C.A.6
-
17
-
-
6844261377
-
Recruitment of topoisomerase I following DNA damage in human cells
-
Muller M., Rosenstein B., Subramaman D. Recruitment of topoisomerase I following DNA damage in human cells. Proc AACR 1996; 37: 637
-
(1996)
Proc AACR
, vol.37
, pp. 637
-
-
Muller, M.1
Rosenstein, B.2
Subramaman, D.3
-
18
-
-
0027425758
-
A phase I trial of carboplatin and etoposide given as continuous infusion to adults with leukemia
-
Lee E., Reck K., Carter C., Hodges S., Schiffer C. A. A phase I trial of carboplatin and etoposide given as continuous infusion to adults with leukemia. Leukemia 1993; 7 (10) 1500 – 3
-
(1993)
Leukemia
, vol.7
, Issue.10
, pp. 1500-1503
-
-
Lee, E.1
Reck, K.2
Carter, C.3
Hodges, S.4
Schiffer, C.A.5
|